Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.

International immunology - 1 Aug 2014

Al-Zoobi Loubna, Salti Suzanne, Colavecchio Anna, Jundi Malek, Nadiri Amal, Hassan Ghada S, El-Gabalawy Hani, Mourad Walid

Abstract excerpt

CD20 is an attractive therapeutic target given the success of its monoclonal antibody, Rituximab, in the treatment of B-cell malignancies and B-cell-mediated autoimmune diseases. Treatment with Rituximab causes a rapid depletion of B cells and a decrease in disease symptoms. Despite the clinical efficiency of Rituximab, its mechanism of action is not completely understood. In this study, we aimed at further...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Murine-Derived
Share to Antigens, CD20

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD40 Antigens

Share to Cell Death

Share to Drug Synergism

Share to Protein Multimerization

Share to Receptors, Fc

Share to Rituximab

Source

Identifiers

PMID: 24894009
DOI: 10.1093/intimm/dxu046

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.PMID 24894009Read ↗

Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular CytotoxicitySemantic proximity Read ↗

Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector MechanismsSemantic proximity Read ↗

Depletion of functionally active CD20+ T cells by rituximab treatment.Semantic proximity Read ↗

Rituximab resistance.Semantic proximity Read ↗

IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodiesSemantic proximity Read ↗

Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.Semantic proximity Read ↗

IRF8 regulates efficacy of therapeutic anti‐CD20 monoclonal antibodiesSemantic proximity Read ↗

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.Semantic proximity Read ↗

Anti-CD19/CD20 bispecific antibody with dual Fc domains mediates enhanced effector functions and durable depletion of memory B cells in vivoSemantic proximity Read ↗

The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapySemantic proximity Read ↗

A type II anti-CD20 monoclonal antibody efficiently depletes CNS B cells in a mouse model of multiple sclerosisSemantic proximity Read ↗

Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.